Selected research
Industry Research
Urate-stimulating Excretion Agents Industry Research Report 2026
Market perspective
The global Urate-stimulating Excretion Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Urate-stimulating Excretion Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Urate-stimulating Excretion Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Urate-stimulating Excretion Agents include Eisai, Teva, Towa Pharmaceutical, Lannett Company, Fuji Yakuhin, Excella and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Urate-stimulating Excretion Agents market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urate-stimulating Excretion Agents Market by Company
Eisai
Teva
Towa Pharmaceutical
Lannett Company
Fuji Yakuhin
Excella
AstraZeneca
Urate-stimulating Excretion Agents Segment by Type
Benzbromarone
Probenecid
Dotinurad
Lesinurad
Other
Urate-stimulating Excretion Agents Segment by Application
Retail Pharmacies
Hospitals and Clinics
Other
Urate-stimulating Excretion Agents Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urate-stimulating Excretion Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urate-stimulating Excretion Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urate-stimulating Excretion Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Urate-stimulating Excretion Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Urate-stimulating Excretion Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Urate-stimulating Excretion Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Benzbromarone
- Probenecid
- Dotinurad
- Lesinurad
- Other
Applications
- Retail Pharmacies
- Hospitals and Clinics
- Other
Companies covered
- Eisai
- Teva
- Towa Pharmaceutical
- Lannett Company
- Fuji Yakuhin
- Excella
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Urate-stimulating Excretion Agents Market Size (2021-2032)
- 2.2.2 Global Urate-stimulating Excretion Agents Sales (2021-2032)
- 2.2.3 Global Urate-stimulating Excretion Agents Market Average Price (2021-2032)
- 2.3 Urate-stimulating Excretion Agents by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Benzbromarone
- 2.3.3 Probenecid
- 2.3.4 Dotinurad
- 2.3.5 Lesinurad
- 2.3.6 Other
- 2.4 Urate-stimulating Excretion Agents by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Hospitals and Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Urate-stimulating Excretion Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urate-stimulating Excretion Agents Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Urate-stimulating Excretion Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Urate-stimulating Excretion Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Urate-stimulating Excretion Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urate-stimulating Excretion Agents, Product Type & Application
- 3.8 Global Manufacturers of Urate-stimulating Excretion Agents, Established Date
- 3.9 Global Urate-stimulating Excretion Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eisai
- 4.1.1 Eisai Company Information
- 4.1.2 Eisai Business Overview
- 4.1.3 Eisai Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eisai Urate-stimulating Excretion Agents Product Portfolio
- 4.1.5 Eisai Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Urate-stimulating Excretion Agents Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Towa Pharmaceutical
- 4.3.1 Towa Pharmaceutical Company Information
- 4.3.2 Towa Pharmaceutical Business Overview
- 4.3.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio
- 4.3.5 Towa Pharmaceutical Recent Developments
- 4.4 Lannett Company
- 4.4.1 Lannett Company Company Information
- 4.4.2 Lannett Company Business Overview
- 4.4.3 Lannett Company Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lannett Company Urate-stimulating Excretion Agents Product Portfolio
- 4.4.5 Lannett Company Recent Developments
- 4.5 Fuji Yakuhin
- 4.5.1 Fuji Yakuhin Company Information
- 4.5.2 Fuji Yakuhin Business Overview
- 4.5.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio
- 4.5.5 Fuji Yakuhin Recent Developments
- 4.6 Excella
- 4.6.1 Excella Company Information
- 4.6.2 Excella Business Overview
- 4.6.3 Excella Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Excella Urate-stimulating Excretion Agents Product Portfolio
- 4.6.5 Excella Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Urate-stimulating Excretion Agents Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
5 Global Urate-stimulating Excretion Agents Market Scenario by Region
- 5.1 Global Urate-stimulating Excretion Agents Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Urate-stimulating Excretion Agents Sales by Region: 2021-2032
- 5.2.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021-2026
- 5.2.2 Global Urate-stimulating Excretion Agents Sales by Region: 2027-2032
- 5.3 Global Urate-stimulating Excretion Agents Revenue by Region: 2021-2032
- 5.3.1 Global Urate-stimulating Excretion Agents Revenue by Region: 2021-2026
- 5.3.2 Global Urate-stimulating Excretion Agents Revenue by Region: 2027-2032
- 5.4 North America Urate-stimulating Excretion Agents Market Facts & Figures by Country
- 5.4.1 North America Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.4.3 North America Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Urate-stimulating Excretion Agents Market Facts & Figures by Country
- 5.5.1 Europe Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.5.3 Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Urate-stimulating Excretion Agents Market Facts & Figures by Country
- 5.6.1 Asia Pacific Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Urate-stimulating Excretion Agents Market Facts & Figures by Country
- 5.7.1 South America Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.7.3 South America Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Urate-stimulating Excretion Agents Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032)
- 6.1.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2032)
- 6.2 Global Urate-stimulating Excretion Agents Revenue by Type (2021-2032)
- 6.2.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2032)
- 6.3 Global Urate-stimulating Excretion Agents Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032)
- 7.1.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2032)
- 7.2 Global Urate-stimulating Excretion Agents Revenue by Application (2021-2032)
- 7.2.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2032)
- 7.3 Global Urate-stimulating Excretion Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Urate-stimulating Excretion Agents Value Chain Analysis
- 8.1.1 Urate-stimulating Excretion Agents Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Urate-stimulating Excretion Agents Production Mode & Process
- 8.2 Urate-stimulating Excretion Agents Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Urate-stimulating Excretion Agents Distributors
- 8.2.3 Urate-stimulating Excretion Agents Customers
9 Global Urate-stimulating Excretion Agents Analyzing Market Dynamics
- 9.1 Urate-stimulating Excretion Agents Industry Trends
- 9.2 Urate-stimulating Excretion Agents Industry Drivers
- 9.3 Urate-stimulating Excretion Agents Industry Opportunities and Challenges
- 9.4 Urate-stimulating Excretion Agents Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst